Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: Correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials

Radiotherapy and Oncology

Volumn 108, Issue 3, 2013, Pages 489-494

  Lassen, Pernille ^a   Overgaard, Jens ^a   Eriksen, Jesper Grau ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

EGFR; HNSCC; HPV; p16; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; NIMORAZOLE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR VOLUME;

EGFR; HNSCC; HPV; P16; RADIOTHERAPY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84887017090     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.08.036     Document Type: Article

References (36)

1. O. Dassonville, J.L. Formento, and M. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873 1878
2. J.G. Eriksen, T. Steiniche, and J. Overgaard The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study Radiother Oncol 73 2005 93 100
3. J.R. Grandis, S.D. Drenning, and A. Chakraborty Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro J Clin Invest 102 1998 1385 1392
4. P. O-Charoenrat, P. Rhys-Evans, H. Modjtahedi, and S. Eccles The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma Oral Oncol 38 2002 627 640
5. S.M. Huang, and P.M. Harari Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results Invest New Drugs 17 1999 259 269
6. K.K. Ang, B.A. Berkey, and X. Tu Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356
7. J.G. Eriksen, T. Steiniche, J. Alsner, J. Askaa, and J. Overgaard The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck Int J Radiat Oncol Biol Phys 58 2004 561 566
8. S.M. Bentzen, B.M. Atasoy, and F.M. Daley Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial J Clin Oncol 23 2005 5560 5567
9. P. Pedicini, A. Nappi, and L. Strigari Correlation between EGFR expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma Radiat Oncol 7 2012 143
10. C.H. Chung, and M.L. Gillison Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications Clin Cancer Res 15 2009 6758 6762
11. J.R. Nevins The Rb/E2F pathway and cancer Hum Mol Genet 10 2001 699 703
12. P. Lassen The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome Radiother Oncol 95 2010 371 380
13. M.L. Gillison, G. D'Souza, and W. Westra Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers J Natl Cancer Inst 100 2008 407 420
14. L.S. Mortensen, J. Johansen, and J. Kallehauge FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial Radiother Oncol 105 2012 14 20
15. P. Lassen, J.G. Eriksen, S. Hamilton-Dutoit, T. Tramm, J. Alsner, and J. Overgaard HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer Radiother Oncol 94 2010 30 35
16. P. Lassen, J.G. Eriksen, and A. Krogdahl The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomized DAHANCA 6&7 trial Radiother Oncol 100 2011 49 55
17. A. Hong, T. Dobbins, and C.S. Lee Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer Eur J Cancer 46 2010 2088 2096
18. R.J. Young, D. Rischin, and R. Fisher Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma Cancer Epidemiol Biomarkers Prev 20 2011 1230 1237
19. J. Overgaard, H.S. Hansen, and M. Overgaard A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the danish head and neck cancer study (DAHANCA) protocol 5-85 Radiother Oncol 46 1998 135 146
20. J. Overgaard, H.S. Hansen, and L. Specht Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomized controlled trial Lancet 362 2003 933 940
21. P. Lassen, J.G. Eriksen, S. Hamilton-Dutoit, T. Tramm, J. Alsner, and J. Overgaard Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck J Clin Oncol 27 2009 1992 1998
22. A.K. El-Naggar, and W.H. Westra P16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency Head Neck 34 2012 459 461
23. P. Lassen, and J. Overgaard Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression Radiother Oncol 105 2012 269 270
24. G. Almadori, G. Cadoni, and P. Cattani Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma Clin Cancer Res 7 2001 3988 3993
25. K.K. Ang, J. Harris, and R. Wheeler Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35
26. B.S. Sorensen, M. Busk, and N. Olthof Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells Radiother Oncol 108 2013 500 505
27. C.M. Hoff Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy Acta Oncol 51 2012 419 432
28. M.L. Gillison, Q. Zhang, and R. Jordan Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer J Clin Oncol 30 2012 2102 2111
29. C.M. Hoff, C. Grau, and J. Overgaard Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma - a prospective study Radiother Oncol 103 2012 38 44
30. P. Baumeister, M. Marte, M. Reiter, C. Welz, S. Schwenk-Zieger, and U. Harreus EGFR and P-GP expression in oropharyngeal mucosa in relation to smoking Anticancer Res 32 2012 1639 1648
31. J.G. Eriksen, T. Steiniche, and J. Overgaard The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma Acta Oncol 44 2005 50 58
32. S.W. Straight, B. Herman, and D.J. McCance The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes J Virol 69 1995 3185 3192
33. R.D. Burk, Z. Chen, and D.K. Van Human papillomaviruses: genetic basis of carcinogenicity Public Health Genomics 12 2009 281 290
34. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
35. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
36. J.G. Eriksen, P. Lassen, and J. Overgaard Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab? Lancet Oncol 11 2010 312 313